Wedbush Forecasts NovoCure's FY2026 Earnings (NASDAQ:NVCR)

NovoCure Limited (NASDAQ:NVCR - Free Report) - Analysts at Wedbush lifted their FY2026 earnings per share (EPS) estimates for NovoCure in a research report issued on Monday, June 2nd. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will post earnings of ($1.56) per share for the year, up from their previous estimate of ($1.57). Wedbush currently has a "Neutral" rating and a $27.00 target price on the stock. The consensus estimate for NovoCure's current full-year earnings is ($1.30) per share.

NovoCure (NASDAQ:NVCR - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.16. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The firm had revenue of $154.99 million for the quarter, compared to the consensus estimate of $147.57 million. During the same quarter in the previous year, the business earned ($0.36) earnings per share. The company's quarterly revenue was up 11.9% on a year-over-year basis.

NVCR has been the topic of a number of other research reports. Wall Street Zen downgraded NovoCure from a "hold" rating to a "sell" rating in a report on Friday, April 25th. JPMorgan Chase & Co. reduced their price target on NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Piper Sandler reduced their price target on NovoCure from $42.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $32.83.

NovoCure Trading Up 3.3%

NASDAQ:NVCR traded up $0.55 during mid-day trading on Thursday, reaching $17.00. 2,844,994 shares of the company's stock traded hands, compared to its average volume of 1,167,110. NovoCure has a 12-month low of $14.17 and a 12-month high of $34.13. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -12.14 and a beta of 0.74. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The company has a 50 day moving average price of $17.36 and a 200-day moving average price of $21.94.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. GeoWealth Management LLC purchased a new position in shares of NovoCure during the 4th quarter worth approximately $27,000. Lindbrook Capital LLC grew its holdings in shares of NovoCure by 189.2% during the 4th quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider's stock worth $55,000 after acquiring an additional 1,213 shares during the period. Blue Trust Inc. grew its holdings in shares of NovoCure by 70.7% during the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider's stock worth $56,000 after acquiring an additional 781 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of NovoCure during the 4th quarter worth approximately $68,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of NovoCure during the 4th quarter worth approximately $70,000. Hedge funds and other institutional investors own 84.61% of the company's stock.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.